Overcoming challenges in transitioning stem cell expansion from the laboratory to commercial production
Sponsor
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
The stem cell field has advanced significantly over the past few decades, and most indications are that it will continue to do so at an ever-increasing pace. As more and more of these discoveries turn into potential therapies, scientists need to overcome challenges to transition these unique cells from laboratory conditions into commercial production. Traditional thinking around commercial production tends towards suspension culture, primarily based on the success of therapeutic protein manufacturing. However, stem cell therapies are significantly more complex. They require more sophisticated manufacturing platforms, and there is not always a one-size-fits all option. Many important considerations need to go into choosing the correct upstream manufacturing platforms including: biological compatibility, cost, time, labor, and analytics. This talk will cover some of these key considerations, as well as provide guidance for choosing the right platform to meet specific stem cell therapy production goals.
- Critical factors in choosing an approach to stem cell expansion, including biological compatibility, labor requirements, and analytics
- The relative advantages and disadvantages of adherent and suspension cell culture technologies for stem cell therapy production
- Discuss key considerations for choosing the right platform for stem cell therapy production
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
